NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CLARINEX D 24 HOUR (desloratadine; pseudoephedrine sulfate) by Merck & Co. is long-acting tricyclic histamine antagonist with selective h 1 -receptor histamine antagonist activity. First approved in 2005.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLARINEX D 24 HOUR is a combination oral extended-release tablet containing desloratadine (a long-acting tricyclic histamine H1-receptor antagonist) and pseudoephedrine sulfate (a decongestant). It is indicated for allergic rhinitis symptoms including nasal congestion, sneezing, and itching. The desloratadine component does not readily cross the blood-brain barrier, minimizing sedation risk.
LOE Approaching
Product is approaching loss of exclusivity; commercial teams should expect resource reallocation toward life-cycle management and generic transition planning rather than expansion initiatives.
Mechanism of Action
long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CLARINEX D 24 HOUR offers limited growth trajectory but provides valuable experience in mature product management, generic transition planning, and cost-containment strategies. This role suits professionals seeking stability over expansion and interested in lifecycle management and managed care negotiations.
Brand Manager
Worked on CLARINEX D 24 HOUR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.